Literature DB >> 22368277

Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein.

Sunita Gulati1, Sarika Agarwal, Shreekant Vasudhev, Peter A Rice, Sanjay Ram.   

Abstract

Gonorrhea, a sexually transmitted disease caused by Neisseria gonorrhoeae, is an important cause of morbidity worldwide. A safe and effective vaccine against gonorrhea is needed because of emerging resistance of gonococci to almost every class of antibiotic. A gonococcal lipooligosaccharide epitope defined by the mAb 2C7 is being evaluated as a candidate for development of an Ab-based vaccine. Immune Abs against N. gonorrhoeae need to overcome several subversive mechanisms whereby gonococcus evades complement, including binding to C4b-binding protein (C4BP; classical pathway inhibitor) and factor H (alternative pathway [AP] inhibitor). The role of AP recruitment and, in particular, properdin in assisting killing of gonococci by specific Abs is the subject of this study. We show that only those gonococcal strains that bind C4BP require properdin for killing by 2C7, whereas strains that do not bind C4BP are efficiently killed by 2C7 even when AP function is blocked. C3 deposition on bacteria mirrored killing. Recruitment of the AP by mAb 2C7, as measured by factor B binding, occurred in a properdin-dependent manner. These findings were confirmed using isogenic mutant strains that differed in their ability to bind to C4BP. Immune human serum that contained bactericidal Abs directed against the 2C7 lipooligosaccharide epitope as well as murine antigonococcal antiserum required functional properdin to kill C4BP-binding strains, but not C4BP-nonbinding strains. Collectively, these data point to an important role for properdin in facilitating immune Ab-mediated complement-dependent killing of gonococcal strains that inhibit the classical pathway by recruiting C4BP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22368277      PMCID: PMC3311752          DOI: 10.4049/jimmunol.1102746

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

2.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

3.  Monoclonal antibody that recognizes an outer membrane antigen common to the pathogenic Neisseria species but not to most nonpathogenic Neisseria species.

Authors:  J G Cannon; W J Black; I Nachamkin; P W Stewart
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

4.  Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils.

Authors:  U Wirthmueller; B Dewald; M Thelen; M K Schäfer; C Stover; K Whaley; J North; P Eggleton; K B Reid; W J Schwaeble
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

5.  Complement alternative pathway acts as a positive feedback amplification of neutrophil activation.

Authors:  Laurent Camous; Lubka Roumenina; Sylvain Bigot; Soumeya Brachemi; Véronique Frémeaux-Bacchi; Philippe Lesavre; Lise Halbwachs-Mecarelli
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

6.  Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal salpingitis.

Authors:  F A Plummer; H Chubb; J N Simonsen; M Bosire; L Slaney; N J Nagelkerke; I Maclean; J O Ndinya-Achola; P Waiyaki; R C Brunham
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

7.  Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects.

Authors:  D P McQuillen; S Gulati; S Ram; A K Turner; D B Jani; T C Heeren; P A Rice
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

8.  DC-SIGN (CD209) recognition of Neisseria gonorrhoeae is circumvented by lipooligosaccharide variation.

Authors:  Pei Zhang; Olivier Schwartz; Milica Pantelic; Geling Li; Quita Knazze; Cinzia Nobile; Milan Radovich; Johnny He; Soon-Cheol Hong; John Klena; Tie Chen
Journal:  J Leukoc Biol       Date:  2006-02-03       Impact factor: 4.962

9.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

10.  Specificity of antibodies against Neisseria gonorrhoeae that stimulate neutrophil chemotaxis. Role of antibodies directed against lipooligosaccharides.

Authors:  P Densen; S Gulati; P A Rice
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

View more
  22 in total

1.  Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae.

Authors:  Jutamas Shaughnessy; Lisa A Lewis; Bo Zheng; Caleb Carr; Isaac Bass; Sunita Gulati; Rosane B DeOliveira; Severin Gose; George W Reed; Marina Botto; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2018-09-28       Impact factor: 5.422

2.  Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic.

Authors:  Jutamas Shaughnessy; David M Vu; Rahi Punjabi; Judit Serra-Pladevall; Rosane B DeOliveira; Dan M Granoff; Sanjay Ram
Journal:  Clin Vaccine Immunol       Date:  2014-08-20

3.  Therapeutic CMP-Nonulosonates against Multidrug-Resistant Neisseria gonorrhoeae.

Authors:  Sunita Gulati; Ian C Schoenhofen; Theresa Lindhout-Djukic; Melissa J Schur; Corinna S Landig; Sudeshna Saha; Lingquan Deng; Lisa A Lewis; Bo Zheng; Ajit Varki; Sanjay Ram
Journal:  J Immunol       Date:  2020-05-20       Impact factor: 5.422

4.  Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model.

Authors:  Sunita Gulati; Xin Mu; Bo Zheng; George W Reed; Sanjay Ram; Peter A Rice
Journal:  J Infect Dis       Date:  2015-01-16       Impact factor: 5.226

5.  Phase-Variable Heptose I Glycan Extensions Modulate Efficacy of 2C7 Vaccine Antibody Directed against Neisseria gonorrhoeae Lipooligosaccharide.

Authors:  Srinjoy Chakraborti; Lisa A Lewis; Andrew D Cox; Frank St Michael; Jianjun Li; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2016-05-02       Impact factor: 5.422

6.  A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae.

Authors:  Jutamas Shaughnessy; Sunita Gulati; Sarika Agarwal; Magnus Unemo; Makoto Ohnishi; Xia-Hong Su; Brian G Monks; Alberto Visintin; Guillermo Madico; Lisa A Lewis; Douglas T Golenbock; George W Reed; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

7.  Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides.

Authors:  Sarika Agarwal; Shreekant Vasudhev; Rosane B DeOliveira; Sanjay Ram
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

Review 8.  Properdin in complement activation and tissue injury.

Authors:  Allison M Lesher; Bo Nilsson; Wen-Chao Song
Journal:  Mol Immunol       Date:  2013-06-29       Impact factor: 4.407

Review 9.  Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae.

Authors:  Sanjay Ram; Jutamas Shaughnessy; Rosane B DeOliveira; Lisa A Lewis; Sunita Gulati; Peter A Rice
Journal:  Immunobiology       Date:  2016-06-01       Impact factor: 3.144

10.  A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.

Authors:  Peter T Beernink; Emma Ispasanie; Lisa A Lewis; Sanjay Ram; Gregory R Moe; Dan M Granoff
Journal:  J Infect Dis       Date:  2019-03-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.